OBJECTIVES: Health technology assessment (HTA) in China has recently expanded from pure academic research to include policy or decision-oriented practice, especially after the use of HTA evidence to update the National Reimbursement Drug List for the first time in 2017. This study aimed to compare changes in the level of HTA development from 2016 to 2021 and to inform policies and decisions to promote further development of HTA in China.

METHODS: We conducted a cross-sectional and anonymous web-based survey to relevant stakeholders in China in 2016 and 2021 respectively. The mapping of HTA instrument was used to reflect the HTA development from eight domains. To reduce the influence of confounders and to compare the mapping outcomes between 2016 and 2021 group, we performed a 1:1 propensity score matching methodology in this study. Univariate analysis was performed to compare the differences in these two groups. We also compared the overall results with that of a mapping study that included ten countries.

RESULTS: A total of 212 and 255 respondents completed the survey in 2016 and 2021 respectively. After propensity score matching methodology, 183 cases from the 2016 group and 2021 group were matched. Overall, the mean score of 2021 in most of the domains was higher than 2016 in China (P<.05), such as the level of HTA institutionalization and dissemination strategy, except for assessment. Although China scored significantly lower among the three developed countries, the overall HTA development score was comparable among the ten countries.

CONCLUSIONS: Our study suggested the level of HTA development in China has made great progress from 2016 to 2021. Prior to HTA activities, more efforts should be made to the assessment process to ensure a higher quality of HTA evidence.